Brincidofovir for disease progression due to suspected tecovirimat resistance in association with advanced HIV

Iris Harrison; Kathryn DeSear; Barbara A Santevecchi; Veena Venugopalan; Kartikeya Cherabuddi; Nicole Iovine; Nila Radhakrishnan

doi:10.1177/09564624241238813

Brincidofovir for disease progression due to suspected tecovirimat resistance in association with advanced HIV

Int J STD AIDS. 2024 Mar 19:9564624241238813. doi: 10.1177/09564624241238813. Online ahead of print.

Authors

Iris Harrison¹, Kathryn DeSear², Barbara A Santevecchi³, Veena Venugopalan³, Kartikeya Cherabuddi⁴, Nicole Iovine⁴, Nila Radhakrishnan⁵

Affiliations

¹ University of Florida College of Medicine, Gainesville, FL, USA.
² Department of Pharmacy, University of Florida Health, Gainesville, FL, USA.
³ Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USA.
⁴ Division of Infectious Diseases & Global Medicine, University of Florida Health, Gainesville, FL, USA.
⁵ Department of Medicine, University of Florida Health, Gainesville, FL, USA.

PMID: 38502040
DOI: 10.1177/09564624241238813

Abstract

A man with advanced HIV presented with verrucous plaques 2-3 months after initial mpox infection. He received two courses of tecovirimat without resolution of initial mpox lesions and development of new lesions raising concern for resistance. He was treated with two doses of brincidofovir and demonstrated improvement 6 months later.

Keywords: HIV/AIDS and other retroviruses; Mpox; brincidofovir; case report; cidofovir; disease outbreaks; sexually transmitted infections; tecovirimat; viruses.